Australia's most trusted
source of pharma news
Posted 3 June 2026 AM
Sydney-based Recce has announced a multi-million-dollar deal is in the works to license an anti-infective for sale across the Middle East and North Africa but is playing coy on who its partner is.
Recce has signed a non-binding term sheet for a ten-year exclusive distribution deal for R327G Topical Gel targeting Diabetic Foot Infections (DFI) for ten countries across the MENA region, with the finalised deal intended to be signed next quarter. It's the first distribution deal for the company, which has signed a couple of R&D deals with the US Army Institute of Surgical Research.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.